OmniAb, Inc. (NASDAQ:OABI – Get Free Report) CEO Matthew W. Foehr bought 95,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was purchased at an average price of $4.27 per share, with a total value of $405,650.00. Following the transaction, the chief executive officer now owns 2,427,919 shares in the company, valued at approximately $10,367,214.13. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
OmniAb Price Performance
NASDAQ:OABI opened at $4.71 on Wednesday. OmniAb, Inc. has a 12-month low of $2.42 and a 12-month high of $5.97. The firm has a market capitalization of $547.16 million, a P/E ratio of -15.70 and a beta of -0.43. The business has a 50 day simple moving average of $4.92 and a 200 day simple moving average of $4.86.
Analysts Set New Price Targets
Several research analysts have recently commented on OABI shares. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research report on Friday, August 11th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, OmniAb presently has a consensus rating of “Buy” and an average price target of $10.00.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new position in OmniAb during the 2nd quarter valued at approximately $38,000. Victory Capital Management Inc. bought a new stake in OmniAb during the 2nd quarter valued at $51,000. Chicago Capital LLC bought a new stake in OmniAb during the 2nd quarter valued at $15,959,000. Simplicity Solutions LLC bought a new stake in OmniAb during the 2nd quarter valued at $80,000. Finally, abrdn plc bought a new stake in OmniAb during the 2nd quarter valued at $522,000. Institutional investors and hedge funds own 58.73% of the company’s stock.
OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
- Five stocks we like better than OmniAb
- Health Care Stocks Explained: Why You Might Want to Invest
- Analyst says Archer Aviation may double. Is it time to buy?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- What is a Secondary Public Offering? What Investors Need to Know
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.